Zhuxin Zhang, Qinglin Hu, Chen Yang, Miao Chen, Bing Han
{"title":"Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China.","authors":"Zhuxin Zhang, Qinglin Hu, Chen Yang, Miao Chen, Bing Han","doi":"10.1177/20406207231191310","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Eltrombopag (ELT), a thrombopoietin receptor agonist (TPO-RA), has been approved for relapsed/refractory aplastic anemia (AA). However, data on avatrombopag (AVA), another TPO-RA, are limited, and the comparisons between the two TPO-RAs are lacking.</p><p><strong>Objectives: </strong>We aimed to compare the efficacy and safety between ELT and AVA in relapsed/refractory AA patients.</p><p><strong>Design: </strong>In this retrospective study, patients with relapsed/refractory AA who had been treated with ELT (<i>N</i> = 45) or AVA (<i>N</i> = 30) alone and had compatible baseline hematological parameters were compared.</p><p><strong>Methods: </strong>Data from patients diagnosed with acquired AA were retrospectively collected. All patients were refractory/relapsed to standard immunosuppressive therapy (IST) for at least 6 months before ELT or AVA. Patients had to be treated with ELT or AVA alone for at least 6 months before evaluation if they did not respond. Baseline characteristics, overall response (OR), complete response (CR), relapse, adverse events, and factors that may affect efficacy were analyzed.</p><p><strong>Results: </strong>Of the 75 patients enrolled, 45 received ELT and 30 received AVA. Patients with AVA had a higher percentage of abnormal liver or renal function than those with ELT (<i>p =</i> 0.036). No significant difference was found in the OR/CR rate in the first/second/third/sixth month between the two cohorts (<i>p ></i> 0.05). Patients treated with AVA had a shorter median time to response than those treated with ELT (<i>p =</i> 0.012) and had a higher platelet level in the second month (<i>p =</i> 0.041). AVA had fewer adverse events than ELT (<i>p =</i> 0.046). Under compatible follow-up time (<i>p =</i> 0.463), no difference was found between the ELT and AVA cohorts in relapse (<i>p =</i> 1.000) or clone evolution (<i>p =</i> 0.637). No predictive factors for OR and CR in the sixth month were found for either ELT or AVA.</p><p><strong>Conclusion: </strong>With worse liver or renal function, AVA had a similar OR/CR rate but a shorter median time to response and fewer adverse events for patients with relapsed/refractory AA.</p>","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":"14 ","pages":"20406207231191310"},"PeriodicalIF":3.4000,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/49/10.1177_20406207231191310.PMC10503291.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207231191310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Eltrombopag (ELT), a thrombopoietin receptor agonist (TPO-RA), has been approved for relapsed/refractory aplastic anemia (AA). However, data on avatrombopag (AVA), another TPO-RA, are limited, and the comparisons between the two TPO-RAs are lacking.
Objectives: We aimed to compare the efficacy and safety between ELT and AVA in relapsed/refractory AA patients.
Design: In this retrospective study, patients with relapsed/refractory AA who had been treated with ELT (N = 45) or AVA (N = 30) alone and had compatible baseline hematological parameters were compared.
Methods: Data from patients diagnosed with acquired AA were retrospectively collected. All patients were refractory/relapsed to standard immunosuppressive therapy (IST) for at least 6 months before ELT or AVA. Patients had to be treated with ELT or AVA alone for at least 6 months before evaluation if they did not respond. Baseline characteristics, overall response (OR), complete response (CR), relapse, adverse events, and factors that may affect efficacy were analyzed.
Results: Of the 75 patients enrolled, 45 received ELT and 30 received AVA. Patients with AVA had a higher percentage of abnormal liver or renal function than those with ELT (p = 0.036). No significant difference was found in the OR/CR rate in the first/second/third/sixth month between the two cohorts (p > 0.05). Patients treated with AVA had a shorter median time to response than those treated with ELT (p = 0.012) and had a higher platelet level in the second month (p = 0.041). AVA had fewer adverse events than ELT (p = 0.046). Under compatible follow-up time (p = 0.463), no difference was found between the ELT and AVA cohorts in relapse (p = 1.000) or clone evolution (p = 0.637). No predictive factors for OR and CR in the sixth month were found for either ELT or AVA.
Conclusion: With worse liver or renal function, AVA had a similar OR/CR rate but a shorter median time to response and fewer adverse events for patients with relapsed/refractory AA.
期刊介绍：
Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
